A 36-week treatment regimen of pegcetacoplan reduces geographic atrophy growth rate while demonstrating a favorable safety profile.

Ocugen ( OCGN -6.48%) Q3 2024 Earnings Call Nov 08, 2024, 8:30 a.m. ET Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator instructions] I will now ...

Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to ...

The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and ...

The US Food and Drug Administration has FDA has granted marketing authorization to a form of light therapy as the first-ever ...

The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com. About Peak Bio, Inc. Peak Bio (OTC: ...

That’s why National Geographic and Rolex have partnered to support trailblazing scientific research, expeditions, and solutions to increase our understanding of the threats facing the planet’s ...